AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27863979
Drug: ADA fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADA fasting glucose concentration cutoff (5.6-6.9 mmol/L)
Trial: 27863979
Drug: WHO fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WHO fasting glucose concentration cutoff (6.1-6.9 mmol/L)
Trial: 18354933
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of intervention
Trial: 18354933
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose of intervention
Trial: 17161044
Drug: Prehospital fibrinolysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prehospital fibrinolysis (PHF); administered within 6 hours of symptom onset by ambulance.
Trial: 17161044
Drug: Inhospital treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhospital treatment
Trial: 26190132
Drug: Medication review
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication review by an experienced hospital pharmacist within the ED
Trial: 17395895
Drug: Dronabinol (DRO),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dronabinol (DRO), 7.5 mg, single dose
Trial: 9743306
Drug: 5‐fluorouracil (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (500 mg m(‐2)), epirubicin (60 mg m(‐2)), cyclophosphamide (500 mg m(‐2)) administered in four weekly doses
Trial: 9743306
Drug: 5‐fluorouracil (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (500 mg m(‐2)), epirubicin (60 mg m(‐2)), cyclophosphamide (500 mg m(‐2)) administered in every‐4‐week dose
Trial: 9743306
Drug: 5‐fluorouracil (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐fluorouracil (500 mg m(‐2)), epirubicin (60 mg m(‐2)), cyclophosphamide (500 mg m(‐2))
Trial: 9815951
Drug: Letrozole 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 0.5 mg/day
Trial: 2299605
Drug: Daily intravesical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intravesical injections of 250 mg of prostaglandin F2 alpha (PGF2 alpha) (n = 23)
Trial: 2299605
Drug: Daily 10‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 10‐mg PGE2 vaginal suppository (n = 22)
Trial: 2299605
Drug: Daily saline
RxNorm normalized name: SODIUM CHLORIDE 0.9 g in 100 mL NASAL AEROSOL, SPRAY [EQUATE DAILY SALINE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily saline injection to the bladder (control group, n = 24)
Trial: 24199747
Drug: Exercise prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise prescription and devices for monitoring of risk factors with a smartphone data portal equipped with a mobile health application
Trial: 21393611
Drug: Low-dose sirolimus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sirolimus plus enalapril and atorvastatin (SRL group, n = 14)
Trial: 21393611
Drug: Low-dose sirolimus
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose sirolimus plus enalapril and atorvastatin (SRL group)
Trial: 21393611
Drug: Enalapril plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril plus atorvastatin (CONTROL group, n = 9)
Trial: 21393611
Drug: Enalapril plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril plus atorvastatin (CONTROL group)
Trial: 19590473
Drug: 1% lignocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lignocaine injections
Trial: 19590473
Drug: N-saline injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-saline injections
Trial: 10868865
Drug: Troglitazone monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone monotherapy (600 mg daily)
Trial: 10868865
Drug: Troglitazone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone with sulfonylurea (600 mg daily)
Trial: 10868865
Drug: Troglitazone with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone with insulin (600 mg daily)
Trial: 10868865
Drug: Troglitazone (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Troglitazone (all combinations, 600 mg daily)
Trial: 1839798
Drug: 17‐beta estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17‐beta estradiol valerianate (E2) (2 mg)
Trial: 1839798
Drug: Micronized E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized E2 (2 mg) plus estriol (E3) (1 mg)
Trial: 6222901
Drug: Aminoglutethimide (AG)
RxNorm normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide (AG) 250 mg twice a day
Trial: 6222901
Drug: Aminoglutethimide (AG)
RxNorm normalized name: Aminoglutethimide
DrugBank: Aminoglutethimide (DB00357)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aminoglutethimide (AG) 250 mg
Trial: 29138224
Drug: Exercise +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise + Metformin (E + M)
Trial: 22067089
Drug: Intensified Medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified Medical therapy
Trial: 22067089
Drug: Standard Medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Medical therapy
Trial: 20861211
Drug: Coffee mannooligosaccharides
RxNorm normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee mannooligosaccharides (MOS) beverage (4 g/d)
Trial: 18227044
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of alanyl-glutamine (Gln) with standard total parenteral nutrition (TPN) for 1 week
Trial: 18227044
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (control) with standard total parenteral nutrition (TPN) for 1 week
Trial: 8560112
Drug: Intravenous Diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Diltiazem (DTZ)
Trial: 8560112
Drug: Intravenous Nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Nitroglycerin (NTG)
Trial: 2075139
Drug: Cimetidine plus
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine plus pirenzepine (50 mg before bedtime)
Trial: 2075139
Drug: Sucralfate (4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (4.0 g daily)
Trial: 20571386
Drug: Nitroimidazole antibiotics
RxNorm normalized name: 2-methyl-5-nitroimidazole-1-ethanol
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitroimidazole antibiotics
Trial: 20571386
Drug: Postoperative immunomodulators
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative immunomodulators and antitumor necrosis factor agents
Trial: 18615321
Drug: Outreach Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outreach Treatment Program (OTP)
Trial: 8677455
Drug: Dose level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 1 (paclitaxel and carboplatin with 6 g/m2 ifosfamide and 5 microg/kg/d filgrastim)
Trial: 8677455
Drug: Dose level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 2 (paclitaxel and carboplatin with 6 g/m2 ifosfamide and 5 microg/kg/d filgrastim)
Trial: 8677455
Drug: Dose level
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose level 3 (paclitaxel and carboplatin with 6 g/m2 ifosfamide and 5 microg/kg/d filgrastim)
Trial: 8677455
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment regimen (paclitaxel and carboplatin with 6 g/m2 ifosfamide and 5 microg/kg/d filgrastim)
Trial: 1990895
Drug: Propofol (1-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1-3 mg.kg-1 injected over 10-30 s)
Trial: 1990895
Drug: Propofol (1-3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1-3 mg.kg-1 injected over 10-30 s) with halothane (1-3%)
Trial: 6760217
Drug: Diclofensine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofensine (mean daily dose of 57.5 mg for 3 weeks)
Trial: 30991863
Drug: Apatinib mesylate
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib mesylate combined with chemotherapy (taxane, irinotecan, and fluorouracil)
Trial: 30991863
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (chemotherapy only: taxane, irinotecan, and fluorouracil)
Trial: 23019834
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate (10 mg/5 mL concentration)
Trial: 8586837
Drug: HIV-1 infected
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HIV-1 infected patients with oral hairy leukoplakia
Trial: 2670657
Drug: Perindopril (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (4 mg o.d.)
Trial: 68225
Drug: Subcuticular polyglycolic
RxNorm normalized name: polyglycolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcuticular polyglycolic acid (P.G.A.) sutures
Trial: 31264313
Drug: 1-g hesperidin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-g hesperidin capsule
Trial: 28514320
Drug: 20 minutes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 minutes of forced air warming plus intravenous fluid warming
Trial: 28514320
Drug: No active
RxNorm normalized name: Aveeno Active Naturals
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active preoperative warming plus intravenous fluid warming
Trial: 27870739
Drug: Angle Labor
RxNorm normalized name: Bos taurus ankle joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angle Labor Pain Questionnaire (A‐LPQ) administered before epidural insertion (Test 1)
Trial: 27870739
Drug: Angle Labor
RxNorm normalized name: Bos taurus ankle joint preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angle Labor Pain Questionnaire (A‐LPQ) administered 20 to 30 minutes after test dose (Test 2)
Trial: 20533147
Drug: Microcurrent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microcurrent therapy (M)
Trial: 8175973
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (S)
Trial: 15286546
Drug: Sivelestat (0.16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sivelestat (0.16 mg.kg(‐1)hr(‐1))
Trial: 9263388
Drug: Intravenously and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously and orally administered trimethoprim
Trial: 8112375
Drug: Lovastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (20 mg per day)
Trial: 3771809
Drug: l-norepinephrine infusion
RxNorm normalized name: L-Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: l-norepinephrine infusion (4 to 16 micrograms/min)
Trial: 27206497
Drug: Cognitive-behavioural therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioural therapy (CBT) preoperative intervention
Trial: 24990275
Drug: Dark chocolate
RxNorm normalized name: Ensure Original Dark Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dark chocolate (40 g, >85% cocoa)
Trial: 24990275
Drug: Milk chocolate
RxNorm normalized name: Meritene Milk Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk chocolate (40 g, ≤35% cocoa)
Trial: 16020940
Drug: Virgin argan
RxNorm normalized name: argan oil
DrugBank: Argan oil (DB14310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virgin argan oil (VAO) 25 g/day for 3 weeks
Trial: 16020940
Drug: Extra virgin
RxNorm normalized name: Jarrow Formulas Extra Virgin Coconut Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra virgin olive oil (EVO) 25 g/day for 3 weeks
Trial: 14623832
Drug: Crutches, early
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crutches, early weight bearing, and non-steroidal anti-inflammatory drugs
Trial: 8874336
Drug: Psychologic distress
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychologic distress screening program with monthly telephone screening and additional psychosocial intervention for high distress patients
Trial: 8874336
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving brief psychosocial intervention from a social worker at initial treatment
Trial: 8874336
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group receiving brief psychosocial intervention from a social worker at initial treatment
Trial: 8874336
Drug: Minimal psychosocial
RxNorm normalized name: Centipeda minima whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal psychosocial intervention at initial treatment
Trial: 1997689
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (4 courses at 28-day intervals of 100 mg/M2 cisplatin, 60 mg/M2 doxorubicin, and 600 mg/M2 cyclophosphamide)
Trial: 6394405
Drug: Ionization with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ionization with diclofenac sodium (150 mg)
Trial: 6394405
Drug: Placebo (ionization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (ionization with saline solution)
Trial: 30867067
Drug: Prebiotic supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic supplementation (10 g/day for healthy subjects, 20 g/day for frail subjects)
Trial: 30867067
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 g/day maltodextrin)
Trial: 24970377
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (100 ml for women, 200 ml for men)
Trial: 22516873
Drug: Sequential ART
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential ART interruptions (arm 2)
Trial: 19681410
Drug: Subarachnoid morphine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subarachnoid morphine, bupivacaine and fentanyl
Trial: 19681410
Drug: Subarachnoid morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subarachnoid morphine and bupivacaine
Trial: 19681410
Drug: Subarachnoid morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subarachnoid morphine only
Trial: 11283049
Drug: double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: double dose of proton pump inhibitor
Trial: 9133967
Drug: Gold sodium
RxNorm normalized name: Gold Sodium Thiomalate
DrugBank: Gold (DB14154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold sodium thiomalate (GSTM) 50 mg weekly
Trial: 12369757
Drug: Glimepiride 2
RxNorm normalized name: glimepiride 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 2 mg
Trial: 24876490
Drug: Psychosocial stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial stimulation intervention (weekly visits from community health workers for 2 years)
Trial: 21092774
Drug: Thoracic endovascular
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic endovascular aortic repair (TEVAR) with optimal medical therapy (n = 72)
Trial: 21092774
Drug: Optimal medical
RxNorm normalized name: Optima Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal medical therapy (n = 68)
Trial: 12867220
Drug: IM fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IM fulvestrant 50 mg
Trial: 12867220
Drug: IM fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IM fulvestrant 125 mg
Trial: 12867220
Drug: IM fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IM fulvestrant 250 mg
Trial: 12867220
Drug: Oral tamoxifen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tamoxifen 20 mg
Trial: 12906937
Drug: 5mg prednisolone
RxNorm normalized name: prednisolone 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5mg prednisolone daily
Trial: 10220832
Drug: Gly‐X‐Y repeat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gly‐X‐Y repeat sequences (active drug)
Trial: 7838040
Drug: Regimen A1
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A1 followed by alternating treatment with regimen B and intensified A1 (group 1)
Trial: 7838040
Drug: Regimen A1
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A1 followed by alternating treatment with regimen C and intensified A1 (group 2)
Trial: 7838040
Drug: Supralethal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supralethal therapy and bone marrow transplantation (BMT) (group 3)
Trial: 2115044
Drug: 6 x
RxNorm normalized name: Mepilex AG 6 x 6"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 x 100 mg testosterone pellets
Trial: 2115044
Drug: 6 x
RxNorm normalized name: Mepilex AG 6 x 6"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 x 200 mg testosterone pellets
Trial: 2115044
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 200 mg testosterone pellets
Trial: 2115044
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg testosterone pellets
Trial: 342729
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid therapy at a dosage of 15 mg/kg/day or more
Trial: 342729
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chenodeoxycholic acid therapy at a dosage of less than 15 mg/kg/day
Trial: 29843840
Drug: Emergency Department
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emergency Department (ED) treatment services
Trial: 17097276
Drug: Antipsychotic withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic withdrawal
Trial: 17097276
Drug: Chronic stable
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic stable antipsychotic treatment
Trial: 17097276
Drug: Medication withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication withdrawal
Trial: 8426406
Drug: Moxisylyte (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxisylyte (10 mg)
Trial: 8426406
Drug: Moxisylyte (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxisylyte (20 mg)
Trial: 8426406
Drug: Moxisylyte (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxisylyte (30 mg)
Trial: 3119443
Drug: Transdermal nitroglycerin
RxNorm normalized name: nitroglycerin Transdermal System
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal nitroglycerin patch system with discontinuous drug release (7.5 mg/24 hours)
Trial: 24579284
Drug: PerioBalance (Lactobacilli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PerioBalance (Lactobacilli reuteri‐CFU of 200 million) lozenges for 28 days
Trial: 24579284
Drug: EvoraKids (Streptococcus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EvoraKids (Streptococcus uberis KJ2, Streptococcus oralis KJ3, Streptococcus rattus JH1 45, > or = 100 million) probiotics chewable tablets for 30 days
Trial: 11350463
Drug: Dolasetron 50
RxNorm normalized name: dolasetron 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron 50 mg orally
Trial: 2686713
Drug: Zofenopril (ZOF),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zofenopril (ZOF), 30 mg, once daily (n = 18)
Trial: 2686713
Drug: Hydrochlorothiazide (HCT),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT), 25 mg, once daily (n = 19)
Trial: 23549581
Drug: Duloxetine 60
RxNorm normalized name: duloxetine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 60 mg daily (initially 30 mg for 1 week, then 60 mg for 4 weeks)
Trial: 21799214
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (0.3 g/kg BM)
Trial: 18645344
Drug: Cold pressor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cold pressor test (CPT) with 0.9% saline solution infusion
Trial: 16437735
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine regimen (Sang Ju Yin and Yu Ping Feng San) taken orally for 14 days
Trial: 16437735
Drug: Control study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control study without TCM treatment
Trial: 10711928
Drug: Aerosol Edmonston‐Zagreb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosol Edmonston‐Zagreb vaccine
Trial: 10711928
Drug: Subcutaneous Edmonston‐Zagreb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Edmonston‐Zagreb vaccine